Management of patients with severe oral mucosal disease.
Kim
Y
Y
University of Pennsylvania School of Dental Medicine, USA.
Greenberg
M S
MS
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D003078:Colchicine / Q000627:therapeutic use; D003622:Dapsone / Q000627:therapeutic use; D006074:Gout Suppressants / Q000627:therapeutic use; D006401:Hematologic Agents / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009061:Mouth Mucosa; D010391:Pemphigoid, Bullous / Q000188:drug therapy*; D010431:Pentoxifylline / Q000627:therapeutic use; D013281:Stomatitis, Aphthous / Q000188:drug therapy*; D013754:Tetracyclines; D013792:Thalidomide / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D006074:Gout Suppressants; D006401:Hematologic Agents; D007166:Immunosuppressive Agents; D013754:Tetracyclines; D013792:Thalidomide; D003622:Dapsone; D010431:Pentoxifylline; D003078:Colchicine